Israel Englander’s Travere Therapeutics TVTX Stock Holding History

Israel Englander’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-15,800	Closed	-$141K	–	6553
2023 Q3	$141K	Buy	+15,800	New	+$223K	﹤0.01%	5236
2022 Q4	–	Sell	-100,000	Closed	-$2.46M	–	7067
2022 Q3	$2.46M	Buy	+100,000	New	+$2.58M	﹤0.01%	3559
2019 Q4	–	Sell	-50,000	Closed	-$579K	–	4646
2019 Q3	$579K	Hold	50,000	–	–	﹤0.01%	3163
2019 Q2	$1M	Buy	+50,000	New	+$987K	﹤0.01%	2811
2016 Q4	–	Sell	-243,500	Closed	-$5.45M	–	3750
2016 Q3	$5.45M	Buy	243,500 +183,500	+306%	+$3.49M	0.01%	1285
2016 Q2	$1.07M	Buy	+60,000	New	+$971K	﹤0.01%	2129

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's TVTX Position: Q2 2026 in Review

Israel Englander opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 84,713 shares worth $4.81M. The stake represents ﹤0.01% of the portfolio and ranks #3030 among its holdings. This is a return to the name: Israel Englander previously reported a position in TVTX as recently as Q4 2025.

Israel Englander first reported a position in TVTX in Q1 2014 and has held it in 46 quarters since. The position peaked at $30M in Q3 2023. 317 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Israel Englander held 84,713 shares of Travere Therapeutics worth $4.81M as of Q2 2026.
Travere Therapeutics was a new Israel Englander position in Q2 2026.
Travere Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3030 holding.
Israel Englander first reported a position in Travere Therapeutics in Q1 2014 and has held it in 46 quarters since.
Israel Englander's Travere Therapeutics position peaked at $30M in Q3 2023.
317 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.